The pharmaceutical world is currently obsessed with speed. If you look at the headlines from this week, everyone is talking about how artificial intelligence and decentralized trials are going to shave years off the drug development timeline. It sounds wonderful on paper. The idea that we can just plug a new molecule into a computer and have a life saving treatment ready by next Tuesday is a seductive one. But as someone who spends a lot of time thinking about the actual mechanics of clinical research, I cannot help but feel that we are focusing on the wrong kind of speed.
Real progress in medicine does not happen in a digital vacuum. It happens in the physical space where a researcher meets a volunteer. While the industry is busy chasing the latest software trends, the most successful projects are often the ones that have mastered something much more traditional: the infrastructure of trust. When we talk about early stage research, especially those complex studies where we are escalating doses across different groups of people, the biggest risks are not found in the code. They are found in the logistical friction of everyday operations.
The Problem with Outsourcing Your Priorities
In the modern corporate world, we have been taught that the leanest company wins. We are told to outsource our labs, our shipping, and our data management to the highest bidder. But in a high stakes environment like a Phase 1 clinical trial, outsourcing often means giving away your control over time.
Imagine you are in the middle of a dose escalation study. You have just finished dosing the first group, and you need to know if it is safe to move to the next level. If your blood samples are sitting on a truck headed to a massive central laboratory halfway across the country, you are no longer in the driver’s seat. You are just another customer in a long line. Your study is subject to someone else’s backlog, someone else’s shipping delays, and someone else’s priorities.
This is why there is such a profound advantage to keeping things close to home. When a company like AXIS Clinicals maintains an in house clinical safety lab, it is doing more than just saving on courier fees. It is claiming ownership of the clock. In an in house setting, the lab results are ready when the study needs them, not when a central lab gets around to them. This kind of localized control is what actually allows for agility. It means that the decision to proceed can be made with quality information in hours rather than days.
Transparency Is Not a Software Feature
We talk about transparency as if it is something you can buy in a box and install on your laptop. We see companies bragging about their new dashboards and data visualization tools as if that is the answer to the industry’s complexity. But true transparency is not about how the data looks; it is about who has access to it and how quickly they can act on it.
I have often seen large research organizations get bogged down in their own hierarchies. By the time a critical piece of safety data moves from the clinic floor to a project manager and then up to a senior executive, the window for a quick decision has already closed. The “corporate lag” is a hidden operational risk that kills momentum and, in some cases, compromises safety.
The more effective approach, and one that leaders like John Pottier have championed, is to flatten that communication structure. When you use a web based eSource or EDC system, you are essentially putting everyone in the same room. The senior vice president can see the same live data as the nurse in the clinical unit. There is no translation layer. There is no waiting for a weekly report. That is what real transparency feels like. It is the ability for a decision maker to look at a screen and know exactly what is happening with a volunteer at that very moment.
The Human Side of Data Collection
As we move toward a more digital future, we have to be careful not to lose the human element of training. We often blame our software for inconsistencies in data, but the software is just a mirror. If you are working with a diverse group of participants (ranging from healthy volunteers to people with diabetes or cardiovascular disorders) the way you collect that data has to be flawless.
A tablet cannot tell if a blood pressure cuff is placed incorrectly. An app cannot sense if a volunteer is feeling slightly off in a way they are not reporting. That comes down to the people on the ground. A strong culture of training and consistent internal rules is what keeps a study on track. You can have the most integrated eSource system in the world, but it is only as good as the person holding the stylus. Consistency across cohorts is a byproduct of human expertise, not just digital synchronization.
Building Readiness into the Community
The biggest bottleneck in drug development today is not the science; it is the recruitment. We are constantly hearing that trials are being delayed because we cannot find enough of the right people at the right time. The traditional way of doing things is to wait until a study is signed and then go out and look for volunteers. It is a reactive, stressful way to work.
The smarter approach is to treat recruitment as a constant conversation with the community. By performing general health screens and engaging with people long before a study is even on the horizon, a company creates a “ready to act” community. You aren’t just looking for participants; you are building a database of people who already know and trust your facility.
Whether it is finding smokers, obese individuals, or post menopausal women, having those relationships established ahead of time is the only way to maintain a truly agile timeline. It turns a major logistical hurdle into a predictable part of the process.
Final Thoughts on Discovery
Ultimately, the future of this industry will be defined by those who can balance high tech tools with high touch management. We need the massive clinical units and the flexible bed capacities to handle the scale of modern research. But more importantly, we need direct communication and localized control that allows us to act on what we find.
Discovery is a messy, unpredictable journey. The best way to navigate it is to keep your tools close, your data transparent, and your focus on the people involved. If we can do that, we will find that the speed we have been looking for was not in the cloud all along—it was right there in the clinic.